A phase2 study of trastumab and TS-1 for HER2-positive advanced gastric cancer - trastumab and TS-1 for HER2-positive advanced gastric cancer

Shimane University Hospital0 个研究点目标入组 20 人开始时间: 2011年8月4日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Past history of drug allergy 2) Women who are pregnant, breastfeeding, or potentially (hoping to become) pregnant 3) R1 operation(histlogically positive PM, OM, LM, VM ) 4) Being treated or in need of treatment with flucytosine, phenytoin or warfarin potassium 5) Patient with clinically obvious infecton 6) Past history of drug allergy of S-1, CDDP and Trastuzumab 7) Heart disease that is serious or requires hospitalization, or history of such disease within past year 8) Chronic diarrhea (watery stool or 4 times or more/day) 9) Massive ascites 10) Multiple bone metastasis 11) Clinical suspicion or previous history of metastasis to brain or meninges 12) Operation within 28day 13) More than one cancer at the same time or more than one cancer at different times separated by a 5-year disease-free interval. However, multiple active cancers do not include carcinoma in situ or skin cancer which is determined to have been cured as a result of treatment. 14,15) Difficulty to join the trial due to psychosis or psychotic symptoms or central nervous system damage 16) requiring steroid drug 17) Active hepatitis type HBs positive 18) Otherwise determined by investigators or site principal investigators to be unsuitable for participation in study

发起方